Paratek Pharmaceuticals, Inc. (PRTK)
Market Cap | 116.10M |
Revenue (ttm) | 116.51M |
Net Income (ttm) | -88.66M |
Shares Out | 55.55M |
EPS (ttm) | -1.72 |
PE Ratio | n/a |
Forward PE | 1.72 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 205,393 |
Open | 2.10 |
Previous Close | 2.11 |
Day's Range | 2.07 - 2.14 |
52-Week Range | 1.60 - 4.37 |
Beta | 1.48 |
Analysts | Buy |
Price Target | 18.36 (+778.47%) |
Earnings Date | Mar 13, 2023 |
About PRTK
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy... [Read more]
Financial Performance
In 2021, PRTK's revenue was $130.16 million, an increase of 177.39% compared to the previous year's $46.92 million. Losses were -$59.08 million, -38.80% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PRTK stock is "Buy." The 12-month stock price forecast is $18.36, which is an increase of 778.47% from the latest price.
News

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections National Healthcare Secur...

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its fir...

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA's effectiveness in th...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follo...

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p...

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
Highlights include data from non-clinical and microbiology programs and real-world patient use

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021

Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 ...

Paratek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)
-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021

Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 ...

Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Pr...

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 ...

China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections
Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?